AxoGen Inc

AXGN remains entrenched in a Stage 4 decline with confirmed lower highs and lower lows under declining EMAs. Price is trading below the 9, 21, and 50 EMAs with no sign of a stable base or extended relief rally. The medium-term bias stays bearish—sell into the continuing breakdown—while short-term execution conditions favor immediate participation in the downside momentum.

• ↑Q1 2026 revenue rose 26.6% YoY to $61.5M.
• ↑Full-year 2026 revenue guidance of ≥$270M (+20% YoY).
• ↓Q1 net loss $19.6M ($0.38/share) raises profitability concerns.